| Year |
Citation |
Score |
| 2024 |
Filderman JN, Taylor JL, Wang J, Zhang Y, Singh P, Ross MA, Watkins SC, Nedal Al Bzour A, Karapetyan L, Kalinski P, Storkus WJ. Antagonism of regulatory ISGs enhances the anti-melanoma efficacy of STING agonists. Frontiers in Immunology. 15: 1334769. PMID 38312842 DOI: 10.3389/fimmu.2024.1334769 |
0.343 |
|
| 2023 |
Dong B, Obermajer N, Tsuji T, Matsuzaki J, Bonura C, Withers H, Long M, Chavel C, Olejniczak SH, Minderman H, Edwards RP, Storkus WJ, Romero P, Kalinski P. NK Receptors Replace CD28 As the Dominant Source of Signal 2 for Cognate Recognition of Cancer Cells by TAA-specific Effector CD8 T Cells. Research Square. PMID 37886562 DOI: 10.21203/rs.3.rs-3399211/v1 |
0.525 |
|
| 2022 |
Vats K, Kruglov O, Sahoo B, Soman V, Zhang J, Shurin GV, Chandran UR, Skums P, Shurin MR, Zelikovsky A, Storkus WJ, Bunimovich YL. Sensory nerves impede the formation of tertiary lymphoid structures and development of protective anti-melanoma immune responses. Cancer Immunology Research. PMID 35834791 DOI: 10.1158/2326-6066.CIR-22-0110 |
0.422 |
|
| 2022 |
Filderman JN, Storkus WJ. Finding the right help in the tumor microenvironment. The Journal of Clinical Investigation. 132. PMID 35703176 DOI: 10.1172/JCI161052 |
0.541 |
|
| 2022 |
Saad M, Lee SJ, Tan AC, El Naqa IM, Hodi FS, Butterfield LH, LaFramboise WA, Storkus W, Karunamurthy AD, Conejo-Garcia J, Hwu P, Streicher H, Sondak VK, Kirkwood JM, Tarhini AA. Enhanced immune activation within the tumor microenvironment and circulation of female high-risk melanoma patients and improved survival with adjuvant CTLA4 blockade compared to males. Journal of Translational Medicine. 20: 253. PMID 35659704 DOI: 10.1186/s12967-022-03450-3 |
0.3 |
|
| 2021 |
Dai E, Zhu Z, Wahed S, Qu Z, Storkus WJ, Guo ZS. Epigenetic modulation of antitumor immunity for improved cancer immunotherapy. Molecular Cancer. 20: 171. PMID 34930302 DOI: 10.1186/s12943-021-01464-x |
0.489 |
|
| 2021 |
Storkus WJ, Maurer D, Lin Y, Ding F, Bose A, Lowe D, Rose A, DeMark M, Karapetyan L, Taylor JL, Chelvanambi M, Fecek RJ, Filderman JN, Looney TJ, Miller L, et al. Dendritic cell vaccines targeting tumor blood vessel antigens in combination with dasatinib induce therapeutic immune responses in patients with checkpoint-refractory advanced melanoma. Journal For Immunotherapy of Cancer. 9. PMID 34782430 DOI: 10.1136/jitc-2021-003675 |
0.337 |
|
| 2021 |
Pontrelli P, Gigante M, Spadaccino F, Netti GS, Saldarelli M, Balducci L, Gigante M, Battaglia M, Storkus WJ, Castellano G, Stallone G, Gesualdo L, Ranieri E. CD40 Cross-Linking Induces Migration of Renal Tumor Cell through Nuclear Factor of Activated T Cells (NFAT) Activation. International Journal of Molecular Sciences. 22. PMID 34445576 DOI: 10.3390/ijms22168871 |
0.402 |
|
| 2021 |
Amouzegar A, Chelvanambi M, Filderman JN, Storkus WJ, Luke JJ. STING Agonists as Cancer Therapeutics. Cancers. 13. PMID 34070756 DOI: 10.3390/cancers13112695 |
0.372 |
|
| 2021 |
Filderman JN, Appleman M, Chelvanambi M, Taylor JL, Storkus WJ. STINGing the Tumor Microenvironment to Promote Therapeutic Tertiary Lymphoid Structure Development. Frontiers in Immunology. 12: 690105. PMID 34054879 DOI: 10.3389/fimmu.2021.690105 |
0.405 |
|
| 2021 |
Chelvanambi M, Fecek RJ, Taylor JL, Storkus WJ. STING agonist-based treatment promotes vascular normalization and tertiary lymphoid structure formation in the therapeutic melanoma microenvironment. Journal For Immunotherapy of Cancer. 9. PMID 33526609 DOI: 10.1136/jitc-2020-001906 |
0.444 |
|
| 2020 |
Maurer DM, Adamik J, Santos PM, Shi J, Shurin MR, Kirkwood JM, Storkus WJ, Butterfield LH. Dysregulated NF-κB-Dependent ICOSL Expression in Human Dendritic Cell Vaccines Impairs T-cell Responses in Patients with Melanoma. Cancer Immunology Research. PMID 33051240 DOI: 10.1158/2326-6066.CIR-20-0274 |
0.416 |
|
| 2020 |
Allen A, Gau D, Francoeur P, Sturm J, Wang Y, Martin R, Maranchie J, Duensing A, Kaczorowski A, Duensing S, Wu L, Lotze MT, Koes D, Storkus WJ, Roy P. Actin-binding protein Profilin1 promotes aggressiveness of clear cell renal cell carcinoma cells. The Journal of Biological Chemistry. PMID 32883810 DOI: 10.1074/Jbc.Ra120.013963 |
0.507 |
|
| 2020 |
Guo ZS, Lotze MT, Zhu Z, Storkus WJ, Song XT. Bi- and Tri-Specific T Cell Engager-Armed Oncolytic Viruses: Next-Generation Cancer Immunotherapy. Biomedicines. 8. PMID 32664210 DOI: 10.3390/Biomedicines8070204 |
0.476 |
|
| 2020 |
Filderman JN, Storkus WJ. Neoepitopes as difference makers for general cancer vaccines? Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 32646923 DOI: 10.1158/1078-0432.Ccr-20-2127 |
0.335 |
|
| 2020 |
Guha I, Bhuniya A, Shukla D, Patidar A, Nandi P, Saha A, Dasgupta S, Ganguly N, Ghosh S, Nair A, Majumdar S, Saha B, Storkus WJ, Baral R, Bose A. Tumor Arrests DN2 to DN3 Pro T Cell Transition and Promotes Its Conversion to Thymic Dendritic Cells by Reciprocally Regulating Notch1 and Ikaros Signaling. Frontiers in Immunology. 11: 898. PMID 32582141 DOI: 10.3389/Fimmu.2020.00898 |
0.594 |
|
| 2020 |
Chelvanambi M, Weinstein AM, Storkus WJ. IL-36 Signaling in the Tumor Microenvironment. Advances in Experimental Medicine and Biology. 1240: 95-110. PMID 32060891 DOI: 10.1007/978-3-030-38315-2_8 |
0.546 |
|
| 2019 |
Hwang MP, Fecek RJ, Qin T, Storkus WJ, Wang Y. Single injection of IL-12 coacervate as an effective therapy against B16-F10 melanoma in mice. Journal of Controlled Release : Official Journal of the Controlled Release Society. PMID 31866503 DOI: 10.1016/J.Jconrel.2019.12.035 |
0.504 |
|
| 2019 |
Razzo BM, Ludwig N, Hong CS, Sharma P, Fabian KP, Fecek RJ, Storkus WJ, Whiteside TL. Tumor-derived exosomes promote carcinogenesis of murine oral squamous cell carcinoma. Carcinogenesis. PMID 31245809 DOI: 10.1093/Carcin/Bgz124 |
0.523 |
|
| 2019 |
Ludwig S, Hong CS, Razzo BM, Fabian KPL, Chelvanambi M, Lang S, Storkus WJ, Whiteside TL. Impact of combination immunochemotherapies on progression of 4NQO-induced murine oral squamous cell carcinoma. Cancer Immunology, Immunotherapy : Cii. PMID 31139925 DOI: 10.1007/S00262-019-02348-2 |
0.539 |
|
| 2019 |
Russell KL, Gorgulho CM, Allen A, Vakaki M, Wang Y, Facciabene A, Lee D, Roy P, Buchser WJ, Appleman LJ, Maranchie J, Storkus WJ, Lotze MT. Inhibiting Autophagy in Renal Cell Cancer and the Associated Tumor Endothelium. Cancer Journal (Sudbury, Mass.). 25: 165-177. PMID 31135523 DOI: 10.1097/Ppo.0000000000000374 |
0.422 |
|
| 2019 |
Guo ZS, Lu B, Guo Z, Giehl E, Feist M, Dai E, Liu W, Storkus WJ, He Y, Liu Z, Bartlett DL. Vaccinia virus-mediated cancer immunotherapy: cancer vaccines and oncolytics. Journal For Immunotherapy of Cancer. 7: 6. PMID 30626434 DOI: 10.1186/S40425-018-0495-7 |
0.443 |
|
| 2018 |
Weinstein AM, Giraldo NA, Petitprez F, Julie C, Lacroix L, Peschaud F, Emile JF, Marisa L, Fridman WH, Storkus WJ, Sautès-Fridman C. Association of IL-36γ with tertiary lymphoid structures and inflammatory immune infiltrates in human colorectal cancer. Cancer Immunology, Immunotherapy : Cii. PMID 30315348 DOI: 10.1007/S00262-018-2259-0 |
0.448 |
|
| 2018 |
Choi J, Beaino W, Fecek R, Fabian K, Laymon CM, Kurland B, Storkus W, Anderson CJ. Combination treatment of VLA-4 targeted radionuclide therapy and immunotherapy in a mouse model of melanoma. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine. PMID 29959213 DOI: 10.2967/Jnumed.118.209510 |
0.576 |
|
| 2018 |
Razzo BM, Hong C, Fabian KP, Ludwig N, Sharma P, Storkus WJ, Whiteside TL. Abstract 1748: Head and neck cancer-derived exosomes facilitate carcinogenesis in the murine 4NQO chemically induced oropharyngeal cancer Cancer Research. 78: 1748-1748. DOI: 10.1158/1538-7445.Am2018-1748 |
0.541 |
|
| 2017 |
Fabian KL, Storkus WJ. Immunotherapeutic Targeting of Tumor-Associated Blood Vessels. Advances in Experimental Medicine and Biology. 1036: 191-211. PMID 29275473 DOI: 10.1007/978-3-319-67577-0_13 |
0.478 |
|
| 2017 |
Weinstein AM, Chen L, Brzana EA, Patil PR, Taylor JL, Fabian KL, Wallace CT, Jones SD, Watkins SC, Lu B, Stroncek DF, Denning TL, Fu YX, Cohen PA, Storkus WJ. Tbet and IL-36γ cooperate in therapeutic DC-mediated promotion of ectopic lymphoid organogenesis in the tumor microenvironment. Oncoimmunology. 6: e1322238. PMID 28680760 DOI: 10.1080/2162402X.2017.1322238 |
0.542 |
|
| 2017 |
Liu Z, Hao X, Zhang Y, Zhang J, Carey CD, Falo LD, Storkus WJ, You Z. Intratumoral delivery of tumor antigen-loaded DC and tumor-primed CD4(+) T cells combined with agonist α-GITR mAb promotes durable CD8(+) T-cell-dependent antitumor immunity. Oncoimmunology. 6: e1315487. PMID 28680744 DOI: 10.1080/2162402X.2017.1315487 |
0.631 |
|
| 2017 |
Guo ZS, Liu Z, Kowalsky S, Feist M, Kalinski P, Lu B, Storkus WJ, Bartlett DL. Oncolytic Immunotherapy: Conceptual Evolution, Current Strategies, and Future Perspectives. Frontiers in Immunology. 8: 555. PMID 28555136 DOI: 10.3389/Fimmu.2017.00555 |
0.517 |
|
| 2017 |
Vujanovic L, Stahl EC, Pardee AD, Geller DA, Tsung A, Watkins SC, Gibson GA, Storkus WJ, Butterfield LH. Tumor-derived α-fetoprotein directly drives human natural killer cell activation and subsequent cell death. Cancer Immunology Research. PMID 28468916 DOI: 10.1158/2326-6066.Cir-16-0216 |
0.807 |
|
| 2017 |
Fabian KP, Chi-Sabins N, Taylor JL, Fecek R, Weinstein A, Storkus WJ. Therapeutic efficacy of combined vaccination against tumor pericyte-associated antigens DLK1 and DLK2 in mice. Oncoimmunology. 6: e1290035. PMID 28405524 DOI: 10.1080/2162402X.2017.1290035 |
0.583 |
|
| 2016 |
Fecek RJ, Storkus WJ. Combination strategies to enhance the potency of monocyte-derived dendritic cell-based cancer vaccines. Immunotherapy. 8: 1205-18. PMID 27605069 DOI: 10.2217/Imt-2016-0071 |
0.416 |
|
| 2016 |
Weinstein AM, Storkus WJ. Biosynthesis and Functional Significance of Peripheral Node Addressin in Cancer-Associated TLO. Frontiers in Immunology. 7: 301. PMID 27555845 DOI: 10.3389/Fimmu.2016.00301 |
0.43 |
|
| 2016 |
Raïch-Regué D, Fabian KP, Watson AR, Fecek RJ, Storkus WJ, Thomson AW. Intratumoral delivery of mTORC2-deficient dendritic cells inhibits B16 melanoma growth by promoting CD8(+) effector T cell responses. Oncoimmunology. 5: e1146841. PMID 27471613 DOI: 10.1080/2162402X.2016.1146841 |
0.599 |
|
| 2016 |
Ghosh T, Barik S, Bhuniya A, Dhar J, Dasgupta S, Ghosh S, Sarkar M, Guha I, Sarkar K, Chakrabarti P, Saha B, Storkus WJ, Baral R, Bose A. Tumor-associated mesenchymal stem cells inhibit naïve T cell expansion by blocking cysteine export from dendritic cells. International Journal of Cancer. PMID 27405489 DOI: 10.1002/Ijc.30265 |
0.628 |
|
| 2016 |
Gigante M, Pontrelli P, Herr W, Gigante M, D'Avenia M, Zaza G, Cavalcanti E, Accetturo M, Lucarelli G, Carrieri G, Battaglia M, Storkus WJ, Gesualdo L, Ranieri E. miR-29b and miR-198 overexpression in CD8(+) T cells of renal cell carcinoma patients down-modulates JAK3 and MCL-1 leading to immune dysfunction. Journal of Translational Medicine. 14: 84. PMID 27063186 DOI: 10.1186/S12967-016-0841-9 |
0.481 |
|
| 2016 |
Baar J, Storkus W, Finke J, Butterfield L, Lazarus H, Reese J, Brufsky A, Downes K, Budd G, Fu P. Abstract OT1-01-02: Pilot trial of a type I polarized autologous dendritic cell vaccine incorporating tumor blood vessel antigen-derived peptides in patients with metastatic breast cancer Cancer Research. 76. DOI: 10.1158/1538-7445.Sabcs15-Ot1-01-02 |
0.55 |
|
| 2016 |
Raveendran S, Fecek R, Carey CD, Storkus WJ. Abstract LB-225: Combination immunotherapy targeting HSP90 DNA-repair client proteins overexpressed in chemotherapy-resistant melanoma Cancer Research. 76. DOI: 10.1158/1538-7445.Am2016-Lb-225 |
0.403 |
|
| 2015 |
Wang X, Zhao X, Feng C, Weinstein A, Xia R, Wen W, Lv Q, Zuo S, Tang P, Yang X, Chen X, Wang H, Zang S, Stollings L, Denning TL, ... ... Storkus W, et al. IL-36γ Transforms the Tumor Microenvironment and Promotes Type 1 Lymphocyte-Mediated Antitumor Immune Responses. Cancer Cell. PMID 26321222 DOI: 10.1016/J.Ccell.2015.07.014 |
0.484 |
|
| 2015 |
Weinstein AM, Storkus WJ. Therapeutic Lymphoid Organogenesis in the Tumor Microenvironment. Advances in Cancer Research. 128: 197-233. PMID 26216634 DOI: 10.1016/Bs.Acr.2015.04.003 |
0.553 |
|
| 2015 |
Zhang Y, Chen G, Liu Z, Tian S, Zhang J, Carey CD, Murphy KM, Storkus WJ, Falo LD, You Z. Genetic Vaccines To Potentiate the Effective CD103+ Dendritic Cell-Mediated Cross-Priming of Antitumor Immunity. Journal of Immunology (Baltimore, Md. : 1950). 194: 5937-47. PMID 25972487 DOI: 10.4049/Jimmunol.1500089 |
0.573 |
|
| 2015 |
Fecek RJ, Wang S, Storkus WJ. Immunotherapeutic targeting of HSP90 client proteins in BRAF-inhibitor resistant melanoma Journal For Immunotherapy of Cancer. 3. DOI: 10.1186/2051-1426-3-S2-P432 |
0.573 |
|
| 2015 |
Baar J, Storkus WJ, Finke J, Butterfield L, Lazarus H, Reese J, Downes K, Budd T, Brufsky A, Fu P. Pilot trial of a type I - polarized autologous dendritic cell vaccine incorporating tumor blood vessel antigen-derived peptides in patients with metastatic breast cancer Journal For Immunotherapy of Cancer. 3. DOI: 10.1186/2051-1426-3-S1-P3 |
0.576 |
|
| 2015 |
Weinstein AM, Storkus WJ. Therapeutic Lymphoid Organogenesis in the Tumor Microenvironment Advances in Cancer Research. DOI: 10.1016/bs.acr.2015.04.003 |
0.331 |
|
| 2014 |
Vujanovic L, Shi J, Kirkwood JM, Storkus WJ, Butterfield LH. Molecular mimicry of MAGE-A6 and Mycoplasma penetrans HF-2 epitopes in the induction of antitumor CD8(+) T-cell responses. Oncoimmunology. 3: e954501. PMID 25960935 DOI: 10.4161/21624011.2014.954501 |
0.791 |
|
| 2014 |
Zhang Y, Tian S, Liu Z, Zhang J, Zhang M, Bosenberg MW, Kedl RM, Waldmann TA, Storkus WJ, Falo LD, You Z. Dendritic cell-derived interleukin-15 is crucial for therapeutic cancer vaccine potency. Oncoimmunology. 3: e959321. PMID 25941586 DOI: 10.4161/21624011.2014.959321 |
0.532 |
|
| 2014 |
Wesa AK, Mandic M, Taylor JL, Moschos S, Kirkwood JM, Kwok WW, Finke JH, Storkus WJ. Circulating Type-1 Anti-Tumor CD4(+) T Cells are Preferentially Pro-Apoptotic in Cancer Patients. Frontiers in Oncology. 4: 266. PMID 25325015 DOI: 10.3389/Fonc.2014.00266 |
0.572 |
|
| 2014 |
Lowe DB, Taylor JL, Storkus WJ. Monitoring antigen-specific T cell responses using real-time PCR. Methods in Molecular Biology (Clifton, N.J.). 1186: 65-74. PMID 25149303 DOI: 10.1007/978-1-4939-1158-5_5 |
0.545 |
|
| 2014 |
Lowe DB, Bose A, Taylor JL, Tawbi H, Lin Y, Kirkwood JM, Storkus WJ. Dasatinib promotes the expansion of a therapeutically superior T-cell repertoire in response to dendritic cell vaccination against melanoma. Oncoimmunology. 3: e27589. PMID 24734217 DOI: 10.4161/Onci.27589 |
0.614 |
|
| 2013 |
Chen L, Fabian KL, Taylor JL, Storkus WJ. Therapeutic use of dendritic cells to promote the extranodal priming of anti-tumor immunity. Frontiers in Immunology. 4: 388. PMID 24348473 DOI: 10.3389/Fimmu.2013.00388 |
0.52 |
|
| 2013 |
Chi Sabins N, Taylor JL, Fabian KP, Appleman LJ, Maranchie JK, Stolz DB, Storkus WJ. DLK1: a novel target for immunotherapeutic remodeling of the tumor blood vasculature. Molecular Therapy : the Journal of the American Society of Gene Therapy. 21: 1958-68. PMID 23896726 DOI: 10.1038/Mt.2013.133 |
0.568 |
|
| 2013 |
Chen L, Taylor JL, Sabins NC, Lowe DB, Qu Y, You Z, Storkus WJ. Extranodal induction of therapeutic immunity in the tumor microenvironment after intratumoral delivery of Tbet gene-modified dendritic cells. Cancer Gene Therapy. 20: 469-77. PMID 23846252 DOI: 10.1038/Cgt.2013.42 |
0.594 |
|
| 2013 |
Bose A, Barik S, Banerjee S, Ghosh T, Mallick A, Bhattacharyya Majumdar S, Goswami KK, Bhuniya A, Banerjee S, Baral R, Storkus WJ, Dasgupta PS, Majumdar S. Tumor-derived vascular pericytes anergize Th cells. Journal of Immunology (Baltimore, Md. : 1950). 191: 971-81. PMID 23785117 DOI: 10.4049/Jimmunol.1300280 |
0.611 |
|
| 2013 |
Janelsins BM, Sumpter TL, Tkacheva OA, Rojas-Canales DM, Erdos G, Mathers AR, Shufesky WJ, Storkus WJ, Falo LD, Morelli AE, Larregina AT. Neurokinin-1 receptor agonists bias therapeutic dendritic cells to induce type 1 immunity by licensing host dendritic cells to produce IL-12. Blood. 121: 2923-33. PMID 23365459 DOI: 10.1182/Blood-2012-07-446054 |
0.44 |
|
| 2012 |
Rao A, Lowe DB, Storkus WJ. Shock block for improved immunotherapy. Oncoimmunology. 1: 1427-1429. PMID 23243617 DOI: 10.4161/Onci.21174 |
0.588 |
|
| 2012 |
Cohen PA, Ko JS, Storkus WJ, Spencer CD, Bradley JM, Gorman JE, McCurry DB, Zorro-Manrique S, Dominguez AL, Pathangey LB, Rayman PA, Rini BI, Gendler SJ, Finke JH. Myeloid-derived suppressor cells adhere to physiologic STAT3- vs STAT5-dependent hematopoietic programming, establishing diverse tumor-mediated mechanisms of immunologic escape. Immunological Investigations. 41: 680-710. PMID 23017141 DOI: 10.3109/08820139.2012.703745 |
0.45 |
|
| 2012 |
Rao A, Taylor JL, Chi-Sabins N, Kawabe M, Gooding WE, Storkus WJ. Combination therapy with HSP90 inhibitor 17-DMAG reconditions the tumor microenvironment to improve recruitment of therapeutic T cells. Cancer Research. 72: 3196-206. PMID 22552283 DOI: 10.1158/0008-5472.Can-12-0538 |
0.848 |
|
| 2012 |
Bose A, Lowe DB, Rao A, Storkus WJ. Combined vaccine+axitinib therapy yields superior antitumor efficacy in a murine melanoma model. Melanoma Research. 22: 236-43. PMID 22504156 DOI: 10.1097/Cmr.0B013E3283538293 |
0.701 |
|
| 2012 |
Zhao X, Bose A, Komita H, Taylor JL, Chi N, Lowe DB, Okada H, Cao Y, Mukhopadhyay D, Cohen PA, Storkus WJ. Vaccines targeting tumor blood vessel antigens promote CD8(+) T cell-dependent tumor eradication or dormancy in HLA-A2 transgenic mice. Journal of Immunology (Baltimore, Md. : 1950). 188: 1782-8. PMID 22246626 DOI: 10.4049/Jimmunol.1101644 |
0.602 |
|
| 2012 |
Qu Y, Chen L, Lowe DB, Storkus WJ, Taylor JL. Combined Tbet and IL12 gene therapy elicits and recruits superior antitumor immunity in vivo. Molecular Therapy : the Journal of the American Society of Gene Therapy. 20: 644-51. PMID 22215017 DOI: 10.1038/Mt.2011.283 |
0.564 |
|
| 2012 |
Tüting T, Austyn J, Storkus WJ, Falo LD. The immunology of DNA vaccines. Methods in Molecular Medicine. 29: 37-64. PMID 21374308 DOI: 10.1385/1-59259-688-6:37 |
0.454 |
|
| 2012 |
Rao A, Kawabe M, Storkus WJ. Abstract 4399: Immunostimulatory effects of HSP90 inhibition: Insights from combinational immunotherapies targeting EphA2 Cancer Research. 72: 4399-4399. DOI: 10.1158/1538-7445.Am2012-4399 |
0.842 |
|
| 2012 |
Taylor JL, Qu Y, Chen L, Lowe DB, Storkus WJ. Abstract 1537: Combined Tbet and IL-12 gene therapy elicits and recruits superior anti-tumor immunityin vivo Cancer Research. 72: 1537-1537. DOI: 10.1158/1538-7445.Am2012-1537 |
0.548 |
|
| 2011 |
Qu Y, Taylor JL, Bose A, Storkus WJ. Therapeutic effectiveness of intratumorally delivered dendritic cells engineered to express the pro-inflammatory cytokine, interleukin (IL)-32. Cancer Gene Therapy. 18: 663-73. PMID 21760628 DOI: 10.1038/Cgt.2011.37 |
0.554 |
|
| 2011 |
Zhao X, Bose A, Komita H, Taylor JL, Kawabe M, Chi N, Spokas L, Lowe DB, Goldbach C, Alber S, Watkins SC, Butterfield LH, Kalinski P, Kirkwood JM, Storkus WJ. Intratumoral IL-12 gene therapy results in the crosspriming of Tc1 cells reactive against tumor-associated stromal antigens. Molecular Therapy : the Journal of the American Society of Gene Therapy. 19: 805-14. PMID 21189473 DOI: 10.1038/Mt.2010.295 |
0.81 |
|
| 2011 |
Bose A, Taylor JL, Alber S, Watkins SC, Garcia JA, Rini BI, Ko JS, Cohen PA, Finke JH, Storkus WJ. Sunitinib facilitates the activation and recruitment of therapeutic anti-tumor immunity in concert with specific vaccination. International Journal of Cancer. Journal International Du Cancer. 129: 2158-70. PMID 21170961 DOI: 10.1002/Ijc.25863 |
0.597 |
|
| 2011 |
Chi N, Taylor J, Maranchie J, Storkus W. Abstract 3466: Tumor pericytes: A novel target for immune therapy in renal cell carcinoma Cancer Research. 71: 3466-3466. DOI: 10.1158/1538-7445.Am2011-3466 |
0.572 |
|
| 2011 |
Rao A, Kawabe M, Storkus WJ. Abstract 1805: Integration of 17-(Dimethylaminoethylamino)-17-demethoxygeldanamycin (17-DMAG) in combinational immunotherapy targeting tumor antigen EphA2 Cancer Research. 71: 1805-1805. DOI: 10.1158/1538-7445.Am2011-1805 |
0.829 |
|
| 2010 |
Chi N, Maranchie JK, Appleman LJ, Storkus WJ. Update on vaccine development for renal cell cancer. Open Access Journal of Urology. 2: 125-41. PMID 24198621 DOI: 10.2147/Rru.S7242 |
0.369 |
|
| 2010 |
Pardee AD, McCurry D, Alber S, Hu P, Epstein AL, Storkus WJ. A therapeutic OX40 agonist dynamically alters dendritic, endothelial, and T cell subsets within the established tumor microenvironment. Cancer Research. 70: 9041-52. PMID 21045144 DOI: 10.1158/0008-5472.Can-10-1369 |
0.839 |
|
| 2010 |
Qu Y, Chen L, Pardee AD, Taylor JL, Wesa AK, Storkus WJ. Intralesional delivery of dendritic cells engineered to express T-bet promotes protective type 1 immunity and the normalization of the tumor microenvironment. Journal of Immunology (Baltimore, Md. : 1950). 185: 2895-902. PMID 20675595 DOI: 10.4049/Jimmunol.1001294 |
0.845 |
|
| 2010 |
Schaubert KL, Price DA, Salkowitz JR, Sewell AK, Sidney J, Asher TE, Blondelle SE, Adams S, Marincola FM, Joseph A, Sette A, Douek DC, Ayyavoo V, Storkus W, Leung MY, et al. Generation of robust CD8+ T-cell responses against subdominant epitopes in conserved regions of HIV-1 by repertoire mining with mimotopes. European Journal of Immunology. 40: 1950-62. PMID 20432235 DOI: 10.1002/Eji.200940079 |
0.431 |
|
| 2010 |
Cavalcanti E, Gigante M, Mancini V, Battaglia M, Ditonno P, Capobianco C, Cincione RI, Selvaggi FP, Herr W, Storkus WJ, Gesualdo L, Ranieri E. JAK3/STAT5/6 pathway alterations are associated with immune deviation in CD8 T cells in renal cell carcinoma patients. Journal of Biomedicine & Biotechnology. 2010: 935764. PMID 20339477 DOI: 10.1155/2010/935764 |
0.583 |
|
| 2010 |
Lipscomb MW, Taylor JL, Goldbach CJ, Watkins SC, Wesa AK, Storkus WJ. DC expressing transgene Foxp3 are regulatory APC. European Journal of Immunology. 40: 480-93. PMID 19941313 DOI: 10.1002/Eji.200939667 |
0.537 |
|
| 2010 |
Qu Y, Lipscomb MW, Taylor JL, Storkus WJ. Abstract 3824: Induction of potent antitumor immunity by intratumoral injection of mT-bet transduced dendritic cells Cancer Research. 70: 3824-3824. DOI: 10.1158/1538-7445.Am10-3824 |
0.603 |
|
| 2010 |
Pardee AD, Epstein AL, Storkus WJ. Abstract 2938: A novel OX40 agonist licenses systemic anti-tumor immunity to overcome local immune suppression induced by well-established tumors Cancer Research. 70: 2938-2938. DOI: 10.1158/1538-7445.Am10-2938 |
0.848 |
|
| 2009 |
Pardee AD, Wesa AK, Storkus WJ. Integrating costimulatory agonists to optimize immune-based cancer therapies. Immunotherapy. 1: 249-64. PMID 20046961 DOI: 10.2217/1750743X.1.2.249 |
0.804 |
|
| 2009 |
Lipscomb MW, Chen L, Taylor JL, Goldbach C, Watkins SC, Kalinski P, Butterfield LH, Wesa AK, Storkus WJ. Ectopic T-bet expression licenses dendritic cells for IL-12-independent priming of type 1 T cells in vitro. Journal of Immunology (Baltimore, Md. : 1950). 183: 7250-8. PMID 19915058 DOI: 10.4049/Jimmunol.0901477 |
0.54 |
|
| 2009 |
Sasaki K, Pardee AD, Qu Y, Zhao X, Ueda R, Kohanbash G, Bailey LM, Okada H, Muthuswamy R, Kalinski P, Basse PH, Falo LD, Storkus WJ. IL-4 suppresses very late antigen-4 expression which is required for therapeutic Th1 T-cell trafficking into tumors. Journal of Immunotherapy (Hagerstown, Md. : 1997). 32: 793-802. PMID 19752754 DOI: 10.1097/Cji.0B013E3181Acec1E |
0.825 |
|
| 2009 |
Wieckowski EU, Visus C, Szajnik M, Szczepanski MJ, Storkus WJ, Whiteside TL. Tumor-derived microvesicles promote regulatory T cell expansion and induce apoptosis in tumor-reactive activated CD8+ T lymphocytes. Journal of Immunology (Baltimore, Md. : 1950). 183: 3720-30. PMID 19692638 DOI: 10.4049/Jimmunol.0900970 |
0.614 |
|
| 2009 |
Kawabe M, Mandic M, Taylor JL, Vasquez CA, Wesa AK, Neckers LM, Storkus WJ. Heat shock protein 90 inhibitor 17-dimethylaminoethylamino-17-demethoxygeldanamycin enhances EphA2+ tumor cell recognition by specific CD8+ T cells. Cancer Research. 69: 6995-7003. PMID 19690146 DOI: 10.1158/0008-5472.Can-08-4511 |
0.807 |
|
| 2009 |
Komita H, Zhao X, Katakam AK, Kumar P, Kawabe M, Okada H, Braughler JM, Storkus WJ. Conditional interleukin-12 gene therapy promotes safe and effective antitumor immunity. Cancer Gene Therapy. 16: 883-91. PMID 19444303 DOI: 10.1038/Cgt.2009.33 |
0.756 |
|
| 2009 |
Gigante M, Blasi A, Loverre A, Mancini V, Battaglia M, Selvaggi FP, Maiorano E, Napoli A, Castellano G, Storkus WJ, Gesualdo L, Ranieri E. Dysfunctional DC subsets in RCC patients: ex vivo correction to yield an effective anti-cancer vaccine. Molecular Immunology. 46: 893-901. PMID 19041139 DOI: 10.1016/J.Molimm.2008.09.015 |
0.536 |
|
| 2008 |
Wesa AK, Herrem CJ, Mandic M, Taylor JL, Vasquez C, Kawabe M, Tatsumi T, Leibowitz MS, Finke JH, Bukowski RM, Bruckheimer E, Kinch MS, Storkus WJ. Enhancement in specific CD8+ T cell recognition of EphA2+ tumors in vitro and in vivo after treatment with ligand agonists. Journal of Immunology (Baltimore, Md. : 1950). 181: 7721-7. PMID 19017961 DOI: 10.4049/Jimmunol.181.11.7721 |
0.845 |
|
| 2008 |
Sasaki K, Pardee AD, Okada H, Storkus WJ. IL-4 inhibits VLA-4 expression on Tc1 cells resulting in poor tumor infiltration and reduced therapy benefit. European Journal of Immunology. 38: 2865-73. PMID 18958887 DOI: 10.1002/Eji.200838334 |
0.809 |
|
| 2008 |
Komita H, Zhao X, Taylor JL, Sparvero LJ, Amoscato AA, Alber S, Watkins SC, Pardee AD, Wesa AK, Storkus WJ. CD8+ T-cell responses against hemoglobin-beta prevent solid tumor growth. Cancer Research. 68: 8076-84. PMID 18829566 DOI: 10.1158/0008-5472.Can-08-0387 |
0.829 |
|
| 2008 |
Sasaki K, Zhao X, Pardee AD, Ueda R, Fujita M, Sehra S, Kaplan MH, Kane LP, Okada H, Storkus WJ. Stat6 signaling suppresses VLA-4 expression by CD8+ T cells and limits their ability to infiltrate tumor lesions in vivo. Journal of Immunology (Baltimore, Md. : 1950). 181: 104-8. PMID 18566374 DOI: 10.4049/Jimmunol.181.1.104 |
0.839 |
|
| 2008 |
Moschos SJ, Mandic M, Kirkwood JM, Storkus WJ, Lotze MT. Focus on FOCIS: Interleukin 2 treatment associated autoimmunity Clinical Immunology. 127: 123-129. PMID 18405863 DOI: 10.1016/J.Clim.2008.02.011 |
0.577 |
|
| 2008 |
Gigante M, Mandic M, Wesa AK, Cavalcanti E, Dambrosio M, Mancini V, Battaglia M, Gesualdo L, Storkus WJ, Ranieri E. Interferon-alpha (IFN-alpha)-conditioned DC preferentially stimulate type-1 and limit Treg-type in vitro T-cell responses from RCC patients. Journal of Immunotherapy (Hagerstown, Md. : 1997). 31: 254-62. PMID 18317362 DOI: 10.1097/Cji.0B013E318167B023 |
0.522 |
|
| 2008 |
Wesa AK, Storkus WJ. Killer dendritic cells: mechanisms of action and therapeutic implications for cancer. Cell Death and Differentiation. 15: 51-7. PMID 17948028 DOI: 10.1038/sj.cdd.4402243 |
0.483 |
|
| 2007 |
Storkus WJ, Herrem C, Kawabe M, Cohen PA, Bukowski RM, Finke JH, Wesa AK. Improving immunotherapy by conditionally enhancing MHC class I presentation of tumor antigen-derived Peptide epitopes. Critical Reviews in Immunology. 27: 485-93. PMID 18197809 DOI: 10.1615/Critrevimmunol.V27.I5.60 |
0.848 |
|
| 2007 |
Vujanovic L, Mandic M, Olson WC, Kirkwood J, Storkus WJ. A mycoplasma peptide elicits heteroclitic CD4+ T cell responses against tumor antigen MAGE-A6 Clinical Cancer Research. 13: 6796-6806. PMID 18006782 DOI: 10.1158/1078-0432.Ccr-07-1909 |
0.785 |
|
| 2007 |
Nakamura Y, Watchmaker P, Urban J, Sheridan B, Giermasz A, Nishimura F, Sasaki K, Cumberland R, Muthuswamy R, Mailliard RB, Larregina AT, Falo LD, Gooding W, Storkus WJ, Okada H, et al. Helper function of memory CD8+ T cells: heterologous CD8+ T cells support the induction of therapeutic cancer immunity. Cancer Research. 67: 10012-8. PMID 17942935 DOI: 10.1158/0008-5472.Can-07-1735 |
0.583 |
|
| 2007 |
Yamaguchi S, Tatsumi T, Takehara T, Sakamori R, Uemura A, Mizushima T, Ohkawa K, Storkus WJ, Hayashi N. Immunotherapy of murine colon cancer using receptor tyrosine kinase EphA2-derived peptide-pulsed dendritic cell vaccines. Cancer. 110: 1469-77. PMID 17685394 DOI: 10.1002/Cncr.22958 |
0.584 |
|
| 2007 |
Atkins MB, Carbone D, Coukos G, Dhodapkar M, Ernstoff MS, Finke J, Gajewski TF, Gollob J, Lotze MT, Storkus W, Weiner LM. Report on the ISBTC mini-symposium on biologic effects of targeted therapeutics. Journal of Immunotherapy (Hagerstown, Md. : 1997). 30: 577-90. PMID 17667521 DOI: 10.1097/Cji.0B013E318064E7B2 |
0.397 |
|
| 2007 |
Sasaki K, Zhu X, Vasquez C, Nishimura F, Dusak JE, Huang J, Fujita M, Wesa A, Potter DM, Walker PR, Storkus WJ, Okada H. Preferential expression of very late antigen-4 on type 1 CTL cells plays a critical role in trafficking into central nervous system tumors. Cancer Research. 67: 6451-8. PMID 17616706 DOI: 10.1158/0008-5472.Can-06-3280 |
0.553 |
|
| 2007 |
Tatsumi T, Takehara T, Yamaguchi S, Sasakawa A, Miyagi T, Jinushi M, Sakamori R, Kohga K, Uemura A, Ohkawa K, Storkus WJ, Hayashi N. Injection of IL-12 gene-transduced dendritic cells into mouse liver tumor lesions activates both innate and acquired immunity. Gene Therapy. 14: 863-71. PMID 17344900 DOI: 10.1038/Sj.Gt.3302941 |
0.604 |
|
| 2007 |
Berhanu A, Huang J, Watkins SC, Okada H, Storkus WJ. Treatment-enhanced CD4+Foxp3+ glucocorticoid-induced TNF receptor family related high regulatory tumor-infiltrating T cells limit the effectiveness of cytokine-based immunotherapy. Journal of Immunology (Baltimore, Md. : 1950). 178: 3400-8. PMID 17339434 DOI: 10.4049/Jimmunol.178.6.3400 |
0.848 |
|
| 2007 |
Popescu I, Macedo C, Abu-Elmagd K, Shapiro R, Hua Y, Thomson AW, Morelli AE, Storkus WJ, Metes D. EBV-specific CD8+ T cell reactivation in transplant patients results in expansion of CD8+ type-1 regulatory T cells. American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons. 7: 1215-23. PMID 17331111 DOI: 10.1111/J.1600-6143.2007.01740.X |
0.544 |
|
| 2007 |
Ranieri E, Gigante M, Storkus WJ, Gesualdo L. Translational mini-review series on vaccines: Dendritic cell-based vaccines in renal cancer. Clinical and Experimental Immunology. 147: 395-400. PMID 17302887 DOI: 10.1111/J.1365-2249.2006.03305.X |
0.461 |
|
| 2007 |
Zhu X, Nishimura F, Sasaki K, Fujita M, Dusak JE, Eguchi J, Fellows-Mayle W, Storkus WJ, Walker PR, Salazar AM, Okada H. Toll like receptor-3 ligand poly-ICLC promotes the efficacy of peripheral vaccinations with tumor antigen-derived peptide epitopes in murine CNS tumor models. Journal of Translational Medicine. 5: 10. PMID 17295916 DOI: 10.1186/1479-5876-5-10 |
0.457 |
|
| 2007 |
Storkus WJ, Falo LD. A 'good death' for tumor immunology. Nature Medicine. 13: 28-30. PMID 17206130 DOI: 10.1038/Nm0107-28 |
0.465 |
|
| 2007 |
Wesa A, Kalinski P, Kirkwood JM, Tatsumi T, Storkus WJ. Polarized type-1 dendritic cells (DC1) producing high levels of IL-12 family members rescue patient TH1-type antimelanoma CD4+ T cell responses in vitro. Journal of Immunotherapy (Hagerstown, Md. : 1997). 30: 75-82. PMID 17198085 DOI: 10.1097/01.Cji.0000211316.15278.6E |
0.577 |
|
| 2007 |
Metes D, Macedo C, Storkus W, Popescu I, Webber S. Efficient Ex Vivo Priming of Naïve Precursors into EBV-specific Type-1 CD8+ T Cell Responses from EBV Seronegative Pediatric HTx Patients Requires IL-12 and IL-27 Clinical Immunology. 123: S174. DOI: 10.1016/J.Clim.2007.03.138 |
0.459 |
|
| 2006 |
Eguchi J, Hatano M, Nishimura F, Zhu X, Dusak JE, Sato H, Pollack IF, Storkus WJ, Okada H. Identification of interleukin-13 receptor alpha2 peptide analogues capable of inducing improved antiglioma CTL responses. Cancer Research. 66: 5883-91. PMID 16740728 DOI: 10.1158/0008-5472.Can-06-0363 |
0.452 |
|
| 2006 |
Berhanu A, Huang J, Alber SM, Watkins SC, Storkus WJ. Combinational FLt3 ligand and granulocyte macrophage colony-stimulating factor treatment promotes enhanced tumor infiltration by dendritic cells and antitumor CD8(+) T-cell cross-priming but is ineffective as a therapy. Cancer Research. 66: 4895-903. PMID 16651446 DOI: 10.1158/0008-5472.Can-05-2384 |
0.858 |
|
| 2006 |
Vujanovic L, Ranieri E, Gambotto A, Olson WC, Kirkwood JM, Storkus WJ. IL-12p70 and IL-18 gene-modified dendritic cells loaded with tumor antigen-derived peptides or recombinant protein effectively stimulate specific Type-1 CD4+ T-cell responses from normal donors and melanoma patients in vitro Cancer Gene Therapy. 13: 798-805. PMID 16645618 DOI: 10.1038/Sj.Cgt.7700964 |
0.795 |
|
| 2006 |
Nishimura F, Dusak JE, Eguchi J, Zhu X, Gambotto A, Storkus WJ, Okada H. Adoptive transfer of type 1 CTL mediates effective anti-central nervous system tumor response: critical roles of IFN-inducible protein-10. Cancer Research. 66: 4478-87. PMID 16618775 DOI: 10.1158/0008-5472.Can-05-3825 |
0.511 |
|
| 2006 |
Wankowicz-Kalinska A, Mailliard RB, Olson K, Graham F, Edington H, Kirkwood JM, Martinek S, Das PK, Storkus WJ. Accumulation of low-avidity anti-melanocortin receptor 1 (anti-MC1R) CD8+ T cells in the lesional skin of a patient with melanoma-related depigmentation. Melanoma Research. 16: 165-74. PMID 16567972 DOI: 10.1097/01.Cmr.0000198452.03957.73 |
0.537 |
|
| 2005 |
Hatano M, Eguchi J, Tatsumi T, Kuwashima N, Dusak JE, Kinch MS, Pollack IF, Hamilton RL, Storkus WJ, Okada H. EphA2 as a glioma-associated antigen: a novel target for glioma vaccines. Neoplasia (New York, N.Y.). 7: 717-22. PMID 16207473 DOI: 10.1593/Neo.05277 |
0.482 |
|
| 2005 |
Huang J, Tatsumi T, Pizzoferrato E, Vujanovic N, Storkus WJ. Nitric oxide sensitizes tumor cells to dendritic cell-mediated apoptosis, uptake, and cross-presentation. Cancer Research. 65: 8461-70. PMID 16166326 DOI: 10.1158/0008-5472.Can-05-0654 |
0.57 |
|
| 2005 |
Warrino DE, Olson WC, Scarrow MI, D'Ambrosio-Brennan LJ, Guido RS, Da Silva DM, Kast WM, Storkus WJ. Human papillomavirus L1L2-E7 virus-like particles partially mature human dendritic cells and elicit E7-specific T-helper responses from patients with cervical intraepithelial neoplasia or cervical cancer in vitro Human Immunology. 66: 762-772. PMID 16112023 DOI: 10.1016/J.Humimm.2005.04.006 |
0.489 |
|
| 2005 |
Kuwashima N, Nishimura F, Eguchi J, Sato H, Hatano M, Tsugawa T, Sakaida T, Dusak JE, Fellows-Mayle WK, Papworth GD, Watkins SC, Gambotto A, Pollack IF, Storkus WJ, Okada H. Delivery of dendritic cells engineered to secrete IFN-alpha into central nervous system tumors enhances the efficacy of peripheral tumor cell vaccines: dependence on apoptotic pathways. Journal of Immunology (Baltimore, Md. : 1950). 175: 2730-40. PMID 16081851 DOI: 10.4049/Jimmunol.175.4.2730 |
0.544 |
|
| 2005 |
Muller-Berghaus J, Olson WC, Moulton RA, Knapp WT, Schadendorf D, Storkus WJ. IL-12 production by human monocyte-derived dendritic cells: Looking at the single cell Journal of Immunotherapy. 28: 306-313. PMID 16000948 DOI: 10.1097/01.Cji.0000163594.74533.10 |
0.49 |
|
| 2005 |
Macedo C, Donnenberg A, Popescu I, Reyes J, Abu-Elmagd K, Shapiro R, Zeevi A, Fung JJ, Storkus WJ, Metes D. EBV-specific memory CD8+ T cell phenotype and function in stable solid organ transplant patients. Transplant Immunology. 14: 109-16. PMID 15935301 DOI: 10.1016/J.Trim.2005.02.001 |
0.519 |
|
| 2005 |
Eguchi J, Kuwashima N, Hatano M, Nishimura F, Dusak JE, Storkus WJ, Okada H. IL-4-transfected tumor cell vaccines activate tumor-infiltrating dendritic cells and promote type-1 immunity. Journal of Immunology (Baltimore, Md. : 1950). 174: 7194-201. PMID 15905564 DOI: 10.4049/Jimmunol.174.11.7194 |
0.496 |
|
| 2005 |
Macedo C, Popescu I, Abu-Elmagd K, Reyes J, Shapiro R, Zeevi A, Berghaus JM, Wang LF, Lu L, Thomson AW, Storkus WJ, Fung JJ, Metes D. Augmentation of type-1 polarizing ability of monocyte-derived dendritic cells from chronically immunosuppressed organ-transplant recipients. Transplantation. 79: 451-9. PMID 15729172 DOI: 10.1097/01.Tp.0000146589.49756.7F |
0.42 |
|
| 2005 |
Herrem CJ, Tatsumi T, Olson KS, Shirai K, Finke JH, Bukowski RM, Zhou M, Richmond AL, Derweesh I, Kinch MS, Storkus WJ. Expression of EphA2 is prognostic of disease-free interval and overall survival in surgically treated patients with renal cell carcinoma. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 11: 226-31. PMID 15671550 |
0.748 |
|
| 2005 |
Kalinski P, Giermasz A, Nakamura Y, Basse P, Storkus WJ, Kirkwood JM, Mailliard RB. Helper role of NK cells during the induction of anticancer responses by dendritic cells. Molecular Immunology. 42: 535-9. PMID 15607810 DOI: 10.1016/J.Molimm.2004.07.038 |
0.523 |
|
| 2005 |
Wesa A, Kalinski P, Kirkwood JM, Storkus WJ. Rescuing Anti-melanoma CD4+ Responses With Type-1 Polarized Dendritic Cells: Essential Roles of Extended IL-12 Family Members Journal of Immunotherapy. 28: 661. DOI: 10.1097/01.Cji.0000191105.81066.35 |
0.422 |
|
| 2005 |
Kalinski P, Mailliard RB, Geskin L, Giermasz A, Nakamura Y, Storkus WJ, Lotze MT, Bartlett DL, Kirkwood JM, Falo LD. Polarized DC1-Based Therapeutic Cancer Vaccines Journal of Immunotherapy. 28: 656. DOI: 10.1097/01.Cji.0000191090.97275.78 |
0.322 |
|
| 2004 |
Zarour HM, Land S, Sander C, Mascari R, Storkus WJ, Shipe-Spotloe J, Stover L, Herberman RB, Agarwala SS, Kirkwood JM. Phase I-II vaccine trial with MHC class II and MHC class I epitopes from Melan-A/MART-1 for patients with metastatic melanoma. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 22: 2524. PMID 28015019 DOI: 10.1200/Jco.2004.22.14_Suppl.2524 |
0.312 |
|
| 2004 |
Hatano M, Kuwashima N, Tatsumi T, Dusak JE, Nishimura F, Reilly KM, Storkus WJ, Okada H. Vaccination with EphA2-derived T cell-epitopes promotes immunity against both EphA2-expressing and EphA2-negative tumors. Journal of Translational Medicine. 2: 40. PMID 15563374 DOI: 10.1186/1479-5876-2-40 |
0.573 |
|
| 2004 |
Pizzoferrato E, Liu Y, Gambotto A, Armstrong MJ, Stang MT, Gooding WE, Alber SM, Shand SH, Watkins SC, Storkus WJ, Yim JH. Ectopic expression of interferon regulatory factor-1 promotes human breast cancer cell death and results in reduced expression of survivin. Cancer Research. 64: 8381-8. PMID 15548708 DOI: 10.1158/0008-5472.Can-04-2223 |
0.432 |
|
| 2004 |
Rayman P, Wesa AK, Richmond AL, Das T, Biswas K, Raval G, Storkus WJ, Tannenbaum C, Novick A, Bukowski R, Finke J. Effect of renal cell carcinomas on the development of type 1 T-cell responses. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 10: 6360S-6S. PMID 15448031 DOI: 10.1158/1078-0432.Ccr-050011 |
0.509 |
|
| 2004 |
Mailliard RB, Wankowicz-Kalinska A, Cai Q, Wesa A, Hilkens CM, Kapsenberg ML, Kirkwood JM, Storkus WJ, Kalinski P. alpha-type-1 polarized dendritic cells: a novel immunization tool with optimized CTL-inducing activity. Cancer Research. 64: 5934-7. PMID 15342370 DOI: 10.1158/0008-5472.Can-04-1261 |
0.431 |
|
| 2004 |
Okada H, Tsugawa T, Sato H, Kuwashima N, Gambotto A, Okada K, Dusak JE, Fellows-Mayle WK, Papworth GD, Watkins SC, Chambers WH, Potter DM, Storkus WJ, Pollack IF. Delivery of interferon-alpha transfected dendritic cells into central nervous system tumors enhances the antitumor efficacy of peripheral peptide-based vaccines. Cancer Research. 64: 5830-8. PMID 15313927 DOI: 10.1158/0008-5472.Can-04-0130 |
0.531 |
|
| 2004 |
Warrino DE, Olson WC, Knapp WT, Scarrow MI, D'Ambrosio-Brennan LJ, Guido RS, Edwards RP, Kast WM, Storkus WJ. Disease-stage variance in functional CD4+ T-cell responses against novel pan-human leukocyte antigen-D region presented human papillomavirus-16 E7 epitopes Clinical Cancer Research. 10: 3301-3308. PMID 15161683 DOI: 10.1158/1078-0432.Ccr-03-0498 |
0.461 |
|
| 2004 |
Finke JH, Tannenbaum C, Storkus W, Rayman P, Das T, Biswas K, Richmond A, Moon C, Thornton M, Gill I, Novick A, Bukowski R. Tumor-induced dysfunction in T lymphocytes: increased sensitivity to apoptosis. Der Urologe. Ausg. A. 43: S131-2. PMID 15148573 DOI: 10.1007/S00120-004-0600-Z |
0.459 |
|
| 2004 |
Metes D, Popescu I, Macedo C, Zeevi A, Shapiro R, Abu-Elmagd K, Storkus WJ, Fung JJ. TYPE-1 POLARIZATION OF CD8+ T CELL RESPONSES AGAINST EBV ANTIGENS IS PRESERVED IN IMMUNOSUPPRESSED STABLE SOLID ORGAN TRANSPLANT RECIPIENTS Transplantation. 78: 68. DOI: 10.1097/00007890-200407271-00187 |
0.425 |
|
| 2004 |
Wesa A, Kalinski P, Kirkwood JM, Storkus WJ. Restoration of TH1 CD4+ T Cell Responses to Melanoma Antigens with Type-1 Polarized Dendritic Cells Journal of Immunotherapy. 27: S34. DOI: 10.1097/00002371-200411000-00124 |
0.535 |
|
| 2004 |
Kalinski P, Mailliard R, Giermasz A, Wankowicz A, Cai Q, Wesa A, Falo L, Storkus W, Kirkwood J. Alpha-Type-1-Polarized DC (αDC1): DC-Based Vaccines with Optimized Anti-Cancer Activity Journal of Immunotherapy. 27: S24. DOI: 10.1097/00002371-200411000-00088 |
0.327 |
|
| 2004 |
Popescu I, Macedo C, Zeevi A, Shapiro R, Abu-Elmagd K, Storkus W, Fung J, Metes D. DC1-Based Protocols for Adoptive Immunotherapy for PTLD Boost Type-1 Anti-EBV CD8+ T Cell Responses in Solid Organ Tranplant Patients Journal of Immunotherapy. 27: S4-S5. DOI: 10.1097/00002371-200411000-00022 |
0.504 |
|
| 2004 |
Albaitero AL, Xi L, Wang J, Godfrey T, Storkus W, Ferris RL. Expression and Immunogenicity of MAGE-3 and MAGE-6 in Squamous Cell Carcinoma of the Head and Neck Otolaryngology–Head and Neck Surgery. 131: P174-P175. DOI: 10.1016/J.Otohns.2004.06.311 |
0.564 |
|
| 2003 |
Tatsumi T, Huang J, Gooding WE, Gambotto A, Robbins PD, Vujanovic NL, Alber SM, Watkins SC, Okada H, Storkus WJ. Intratumoral delivery of dendritic cells engineered to secrete both interleukin (IL)-12 and IL-18 effectively treats local and distant disease in association with broadly reactive Tc1-type immunity. Cancer Research. 63: 6378-86. PMID 14559827 |
0.51 |
|
| 2003 |
Popescu I, Macedo C, Zeevi A, Nellis J, Patterson KR, Logar A, Rowe D, Reyes J, Rao AS, Storkus WJ, Fung JJ, Metes D. Ex vivo priming of naïve T cells into EBV-specific Th1/Tc1 effector cells by mature autologous DC loaded with apoptotic/necrotic LCL. American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons. 3: 1369-77. PMID 14525597 DOI: 10.1046/J.1600-6135.2003.00252.X |
0.706 |
|
| 2003 |
Mailliard RB, Son YI, Redlinger R, Coates PT, Giermasz A, Morel PA, Storkus WJ, Kalinski P. Dendritic cells mediate NK cell help for Th1 and CTL responses: two-signal requirement for the induction of NK cell helper function. Journal of Immunology (Baltimore, Md. : 1950). 171: 2366-73. PMID 12928383 DOI: 10.4049/Jimmunol.171.5.2366 |
0.524 |
|
| 2003 |
Tatsumi T, Herrem CJ, Olson WC, Finke JH, Bukowski RM, Kinch MS, Ranieri E, Storkus WJ. Disease stage variation in CD4+ and CD8+ T-cell reactivity to the receptor tyrosine kinase EphA2 in patients with renal cell carcinoma Cancer Research. 63: 4481-4489. PMID 12907621 |
0.826 |
|
| 2003 |
Nakahara N, Pollack IF, Storkus WJ, Wakabayashi T, Yoshida J, Okada H. Effective induction of antiglioma cytotoxic T cells by coadministration of interferon-beta gene vector and dendritic cells. Cancer Gene Therapy. 10: 549-58. PMID 12833135 DOI: 10.1038/Sj.Cgt.7700598 |
0.542 |
|
| 2003 |
Wankowicz-Kalinska A, Le Poole C, van den Wijngaard R, Storkus WJ, Das PK. Melanocyte-specific immune response in melanoma and vitiligo: two faces of the same coin? Pigment Cell Research / Sponsored by the European Society For Pigment Cell Research and the International Pigment Cell Society. 16: 254-60. PMID 12753398 DOI: 10.1034/J.1600-0749.2003.00038.X |
0.365 |
|
| 2003 |
Wańkowicz-Kalińska A, van den Wijngaard RM, Tigges BJ, Westerhof W, Ogg GS, Cerundolo V, Storkus WJ, Das PK. Immunopolarization of CD4+ and CD8+ T cells to Type-1-like is associated with melanocyte loss in human vitiligo. Laboratory Investigation; a Journal of Technical Methods and Pathology. 83: 683-95. PMID 12746478 DOI: 10.1097/01.Lab.0000069521.42488.1B |
0.496 |
|
| 2003 |
Tatsumi T, Kierstead LS, Ranieri E, Gesualdo L, Schena FP, Finke JH, Bukowski RM, Brusic V, Sidney J, Sette A, Logan TF, Kasamon YL, Slingluff CL, Kirkwood JM, Storkus WJ. MAGE-6 encodes HLA-DRbeta1*0401-presented epitopes recognized by CD4+ T cells from patients with melanoma or renal cell carcinoma. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 9: 947-54. PMID 12631591 |
0.541 |
|
| 2002 |
Asai T, Storkus WJ, Mueller-Berghaus J, Knapp W, DeLeo AB, Chikamatsu K, Whiteside TL. In vitro generated cytolytic T lymphocytes reactive against head and neck cancer recognize multiple epitopes presented by HLA-A2, including peptides derived from the p53 and MDM-2 proteins. Cancer Immunity. 2: 3. PMID 12747748 |
0.41 |
|
| 2002 |
Tatsumi T, Storkus WJ. Dendritic cell-based vaccines and therapies for cancer. Expert Opinion On Biological Therapy. 2: 919-28. PMID 12517270 DOI: 10.1517/14712598.2.8.919 |
0.478 |
|
| 2002 |
Tatsumi T, Gambotto A, Robbins PD, Storkus WJ. Interleukin 18 gene transfer expands the repertoire of antitumor Th1-type immunity elicited by dendritic cell-based vaccines in association with enhanced therapeutic efficacy. Cancer Research. 62: 5853-8. PMID 12384548 |
0.461 |
|
| 2002 |
Bykovskaia SN, Shurin GV, Graner S, Bunker ML, Olson W, Thomas R, Shurin MR, Marks S, Storkus WJ, Shogan J. Differentiation of immunostimulatory stem-cell- and monocyte-derived dendritic cells involves maturation of intracellular compartments responsible for antigen presentation and secretion. Stem Cells (Dayton, Ohio). 20: 380-93. PMID 12351809 DOI: 10.1634/Stemcells.20-5-380 |
0.524 |
|
| 2002 |
Tatsumi T, Kierstead LS, Ranieri E, Gesualdo L, Schena FP, Finke JH, Bukowski RM, Mueller-Berghaus J, Kirkwood JM, Kwok WW, Storkus WJ. Disease-associated bias in T helper type 1 (Th1)/Th2 CD4(+) T cell responses against MAGE-6 in HLA-DRB10401(+) patients with renal cell carcinoma or melanoma. The Journal of Experimental Medicine. 196: 619-28. PMID 12208877 DOI: 10.1084/Jem.20012142 |
0.566 |
|
| 2002 |
Lokshin AE, Kalinski P, Sassi RR, Mailliard RB, Müller-Berghaus J, Storkus WJ, Peng X, Marrangoni AM, Edwards RP, Gorelik E. Differential regulation of maturation and apoptosis of human monocyte-derived dendritic cells mediated by MHC class II. International Immunology. 14: 1027-37. PMID 12202400 DOI: 10.1093/Intimm/Dxf073 |
0.439 |
|
| 2002 |
Björck P, Lie WR, Woulfe SL, Klein BK, Olson W, Storkus WJ. Progenipoietin-generated dendritic cells exhibit anti-tumor efficacy in a therapeutic murine tumor model. International Journal of Cancer. 100: 586-91. PMID 12124809 DOI: 10.1002/Ijc.10529 |
0.493 |
|
| 2002 |
Keilholz U, Weber J, Finke JH, Gabrilovich DI, Kast WM, Disis ML, Kirkwood JM, Scheibenbogen C, Schlom J, Maino VC, Lyerly HK, Lee PP, Storkus W, Marincola F, Worobec A, et al. Immunologic monitoring of cancer vaccine therapy: results of a workshop sponsored by the Society for Biological Therapy. Journal of Immunotherapy (Hagerstown, Md. : 1997). 25: 97-138. PMID 12074049 DOI: 10.1097/00002371-200203000-00001 |
0.438 |
|
| 2002 |
Hoffmann TK, Müller-Berghaus J, Ferris RL, Johnson JT, Storkus WJ, Whiteside TL. Alterations in the frequency of dendritic cell subsets in the peripheral circulation of patients with squamous cell carcinomas of the head and neck. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 8: 1787-93. PMID 12060618 |
0.362 |
|
| 2002 |
Bennouna J, Hildesheim A, Chikamatsu K, Gooding W, Storkus WJ, Whiteside TL. Application of IL-5 ELISPOT assays to quantification of antigen-specific T helper responses. Journal of Immunological Methods. 261: 145-56. PMID 11861073 DOI: 10.1016/S0022-1759(01)00566-X |
0.522 |
|
| 2002 |
Mailliard RB, Egawa S, Cai Q, Kalinska A, Bykovskaya SN, Lotze MT, Kapsenberg ML, Storkus WJ, Kalinski P. Complementary dendritic cell-activating function of CD8+ and CD4+ T cells: helper role of CD8+ T cells in the development of T helper type 1 responses. The Journal of Experimental Medicine. 195: 473-83. PMID 11854360 DOI: 10.1084/Jem.20011662 |
0.559 |
|
| 2002 |
Lu G, Janjic BM, Janjic J, Whiteside TL, Storkus WJ, Vujanovic NL. Innate direct anticancer effector function of human immature dendritic cells. II. Role of TNF, lymphotoxin-α1β2, Fas ligand, and TNF-related apoptosis-inducing ligand Journal of Immunology. 168: 1831-1839. PMID 11823516 DOI: 10.4049/Jimmunol.168.4.1831 |
0.445 |
|
| 2002 |
Janjic BM, Lu G, Pimenov A, Whiteside TL, Storkus WJ, Vujanovic NL. Innate direct anticancer effector function of human immature dendritic cells. I. Involvement of an apoptosis-inducing pathway. Journal of Immunology (Baltimore, Md. : 1950). 168: 1823-30. PMID 11823515 DOI: 10.4049/Jimmunol.168.4.1823 |
0.493 |
|
| 2002 |
Kierstead LS, Ranieri E, Olson W, Brusic V, Sidney J, Sette A, Kasamon YL, Slingluff CL, Kirkwood JM, Storkus WJ. gp100/pmel17 and tyrosinase encode multiple epitopes recognized by Th1-type CD4+T cells. British Journal of Cancer. 85: 1738-45. PMID 11742496 DOI: 10.1054/Bjoc.2001.2160 |
0.567 |
|
| 2001 |
Hoffmann TK, Meidenbauer N, Müller-Berghaus J, Storkus WJ, Whiteside TL. Proinflammatory Cytokines and CD40 Ligand Enhance Cross-Presentation and Cross-Priming Capability of Human Dendritic Cells Internalizing Apoptotic Cancer Cells. Journal of Immunotherapy : Official Journal of the Society For Biological Therapy. 24: 162-171. PMID 11449073 DOI: 10.1097/00002371-200103000-00011 |
0.573 |
|
| 2001 |
Larregina AT, Watkins SC, Erdos G, Spencer LA, Storkus WJ, Beer Stolz D, Falo LD. Direct transfection and activation of human cutaneous dendritic cells Gene Therapy. 8: 608-617. PMID 11320407 DOI: 10.1038/Sj.Gt.3301404 |
0.454 |
|
| 2001 |
Metes D, Storkus WJ, Zeevi A, Watkins S, Patterson K, Nellis J, Logar A, Fung JJ, Rao AS. Use of autologous dendritic cells loaded with apoptotic LCL for ex vivo generation of specific CTL from the PBMC of EBV(-) individuals. Transplantation Proceedings. 33: 441. PMID 11266900 DOI: 10.1016/S0041-1345(00)02084-4 |
0.599 |
|
| 2001 |
Le PT, Adams KL, Zaya N, Mathews HL, Storkus WJ, Ellis TM. Human thymic epithelial cells inhibit IL-15- and IL-2-driven differentiation of NK cells from the early human thymic progenitors. Journal of Immunology (Baltimore, Md. : 1950). 166: 2194-201. PMID 11160272 DOI: 10.4049/Jimmunol.166.4.2194 |
0.507 |
|
| 2001 |
Metes D, Storkus W, Zeevi A, Patterson K, Logar A, Rowe D, Nalesnik MA, Fung JJ, Rao AS. Ex vivo generation of effective Epstein-Barr virus (EBV)-specific CD8+ cytotoxic T lymphocytes from the peripheral blood of immunocompetent Epstein Barr virus-seronegative individuals. Transplantation. 70: 1507-15. PMID 11118098 DOI: 10.1097/00007890-200011270-00019 |
0.398 |
|
| 2000 |
Ranieri E, Kierstead LS, Zarour H, Kirkwood JM, Lotze MT, Whiteside T, Storkus WJ. Dendritic cell/peptide cancer vaccines: clinical responsiveness and epitope spreading. Immunological Investigations. 29: 121-5. PMID 10854179 DOI: 10.3109/08820130009062294 |
0.381 |
|
| 2000 |
Asai T, Storkus WJ, Whiteside TL. Evaluation of the modified ELISPOT assay for gamma interferon production in cancer patients receiving antitumor vaccines. Clinical and Diagnostic Laboratory Immunology. 7: 145-54. PMID 10702485 DOI: 10.1128/Cdli.7.2.145-154.2000 |
0.489 |
|
| 2000 |
Zarour HM, Kirkwood JM, Kierstead LS, Herr W, Brusic V, Slingluff CL, Sidney J, Sette A, Storkus WJ. Melan-A/MART-1(51-73) represents an immunogenic HLA-DR4-restricted epitope recognized by melanoma-reactive CD4(+) T cells. Proceedings of the National Academy of Sciences of the United States of America. 97: 400-5. PMID 10618430 DOI: 10.1073/Pnas.97.1.400 |
0.551 |
|
| 2000 |
Dong X, An B, Salvucci Kierstead L, Storkus WJ, Amoscato AA, Salter RD. Modification of the amino terminus of a class II epitope confers resistance to degradation by CD13 on dendritic cells and enhances presentation to T cells. Journal of Immunology (Baltimore, Md. : 1950). 164: 129-35. PMID 10605003 DOI: 10.4049/Jimmunol.164.1.129 |
0.45 |
|
| 2000 |
Herr W, Ranieri E, Olson W, Zarour H, Gesualdo L, Storkus WJ. Mature dendritic cells pulsed with freeze–thaw cell lysates define an effective in vitro vaccine designed to elicit EBV-specific CD4+ and CD8+ T lymphocyte responses Blood. 96: 1857-1864. DOI: 10.1182/Blood.V96.5.1857 |
0.612 |
|
| 2000 |
Metes D, Storkus W, Zeevi A, Watkins S, Patterson K, Nellis J, Logar A, Fung J, Rao A. THE NOVEL USE OF AUTOLOGOUS DENDRITIC CELLS LOADED WITH APOPTOTIC LCL FOR EX VIVO GENERATION OF SPECIFIC CTL FROM THE PBMC OF EBV INDIVIDUALS. Transplantation. 69: S275. DOI: 10.1097/00007890-200004271-00629 |
0.38 |
|
| 1999 |
Ranieri E, Herr W, Gambotto A, Olson W, Rowe D, Robbins PD, Kierstead LS, Watkins SC, Gesualdo L, Storkus WJ. Dendritic cells transduced with an adenovirus vector encoding Epstein-Barr virus latent membrane protein 2B: a new modality for vaccination. Journal of Virology. 73: 10416-25. PMID 10559360 DOI: 10.1128/Jvi.73.12.10416-10425.1999 |
0.563 |
|
| 1999 |
Herr W, Ranieri E, Gambotto A, Kierstead LS, Amoscato AA, Gesualdo L, Storkus WJ. Identification of naturally processed and HLA-presented Epstein-Barr virus peptides recognized by CD4(+) or CD8(+) T lymphocytes from human blood. Proceedings of the National Academy of Sciences of the United States of America. 96: 12033-8. PMID 10518571 DOI: 10.1073/Pnas.96.21.12033 |
0.572 |
|
| 1999 |
Tüting T, Gambotto A, Robbins PD, Storkus WJ, DeLeo AB. Co-delivery of T helper 1-biasing cytokine genes enhances the efficacy of gene gun immunization of mice: studies with the model tumor antigen beta-galactosidase and the BALB/c Meth A p53 tumor-specific antigen. Gene Therapy. 6: 629-636. PMID 10476222 DOI: 10.1038/Sj.Gt.3300859 |
0.479 |
|
| 1999 |
Tüting T, Gambotto A, DeLeo A, Lotze MT, Robbins PD, Storkus WJ. Induction of tumor antigen-specific immunity using plasmid DNA immunization in mice. Cancer Gene Therapy. 6: 73-80. PMID 10078966 DOI: 10.1038/Sj.Cgt.7700020 |
0.462 |
|
| 1999 |
Tüting T, Wilson CC, Martin DM, Baar J, DeLeo A, Lotze MT, Storkus WJ. DNA vaccines targeting dendritic cells for the immunotherapy of cancer. Advances in Experimental Medicine and Biology. 451: 295-304. PMID 10026887 DOI: 10.1007/978-1-4615-5357-1_46 |
0.572 |
|
| 1999 |
Metes D, Zeevi A, Nalesnik MA, Storkus W, Fung JJ, Rao AS. A NOVEL APPROACH TO GENERATE (EX VIVO) EBV-SPECIFIC CYTOTOXIC T CELLS FROM A NAÏVE IMMUNOCOMPETENT EBV-NEGATIVE INDIVIDUAL Transplantation. 67: S234. DOI: 10.1097/00007890-199904150-00933 |
0.442 |
|
| 1999 |
Zarour HM, Storkus WJ, Kirkwood JM. A NOVEL HLA-DR-RESTRICTED MELAN-A/MART-1 ANTIGEN REPRESENTS AN IMMUNOGENIC EPITOPE RECOGNIZED BY MELANOMA-SPECIFIC CD4+ T CELLS Journla of Immunotherapy. 22: 471. DOI: 10.1097/00002371-199909000-00076 |
0.518 |
|
| 1999 |
Asai T, Baba K, Whiteside T, Storkus W. In vitro generation of HLA-A2 restricted cytolytic T lympho-cytes using an HLA-A2+ allogeneic SCCHN cell line for lymphocyte stimulation European Journal of Cancer. 35: S357. DOI: 10.1016/S0959-8049(99)81862-0 |
0.362 |
|
| 1998 |
Falo LD, Storkus WJ. Giving DNA vaccines a helping hand. Nature Medicine. 4: 1239-40. PMID 9809542 DOI: 10.1038/3217 |
0.342 |
|
| 1998 |
Tüting T, Storkus WJ, Falo LD. DNA immunization targeting the skin: molecular control of adaptive immunity. The Journal of Investigative Dermatology. 111: 183-8. PMID 9699714 DOI: 10.1046/J.1523-1747.1998.00261.X |
0.408 |
|
| 1998 |
Tjandrawan T, Martin DM, Maeurer MJ, Castelli C, Lotze MT, Storkus WJ. Autologous human dendriphages pulsed with synthetic or natural tumor peptides elicit tumor-specific CTLs in vitro. Journal of Immunotherapy (Hagerstown, Md. : 1997). 21: 149-57. PMID 9551367 DOI: 10.1097/00002371-199803000-00009 |
0.434 |
|
| 1998 |
Myers JN, Mank-Seymour A, Zitvogel L, Storkus W, Clarke M, Johnson CS, Tahara H, Lotze MT. Interleukin-12 gene therapy prevents establishment of SCC VII squamous cell carcinomas, inhibits tumor growth, and elicits long-term antitumor immunity in syngeneic C3H mice. The Laryngoscope. 108: 261-8. PMID 9473079 DOI: 10.1097/00005537-199802000-00019 |
0.493 |
|
| 1998 |
Takayama T, Nishioka Y, Lu L, Storkus WJ, Lotze MT, Tahara H, Thomson AW. VIRAL IL-10 GENE TRANSDUCTION MARKEDLY INHIBITS THE ALLOSTIMULATORY ACTIVITY OF DENDRITIC CELLS. Transplantation. 65: 258. DOI: 10.1097/00007890-199805131-00714 |
0.374 |
|
| 1998 |
Tüting T, Gambotto A, DeLeo AB, Storkus WJ. Adjuvant administration of plasmid DNA expressing IL-12 enhances the induction of anti-melanoma immune responses with plasmid DNA encoding the murine melanosomal protein TRP-2 Journal of Dermatological Science. 16: S14. DOI: 10.1016/S0923-1811(98)83081-8 |
0.328 |
|
| 1997 |
Tüting T, Gambotto A, Baar J, Davis ID, Storkus WJ, Zavodny PJ, Narula S, Tahara H, Robbins PD, Lotze MT. Interferon-α gene therapy for cancer: retroviral transduction of fibroblasts and particle-mediated transfection of tumor cells are both effective strategies for gene delivery in murine tumor models Gene Therapy. 4: 1053-1060. PMID 9415311 DOI: 10.1038/Sj.Gt.3300509 |
0.472 |
|
| 1997 |
Tüting T, DeLeo AB, Lotze MT, Storkus WJ. Genetically modified bone marrow-derived dendritic cells expressing tumor-associated viral or "self" antigens induce antitumor immunity in vivo. European Journal of Immunology. 27: 2702-7. PMID 9368629 DOI: 10.1002/Eji.1830271033 |
0.541 |
|
| 1997 |
Lotze MT, Shurin M, Davis I, Amoscato A, Storkus WJ. Dendritic cell based therapy of cancer. Advances in Experimental Medicine and Biology. 417: 551-69. PMID 9286419 DOI: 10.1007/978-1-4757-9966-8_91 |
0.52 |
|
| 1997 |
Tüting T, Zorina T, Ma DI, Wilson CC, De Cesare CM, De Leo AB, Lotze MT, Storkus WJ. Development of dendritic cell-based genetic vaccines for cancer. Advances in Experimental Medicine and Biology. 417: 511-8. PMID 9286412 DOI: 10.1007/978-1-4757-9966-8_84 |
0.495 |
|
| 1997 |
Wilson CC, Tueting T, Ma D, Haluszczak C, Lotze M, Storkus W. Activation of Dendritic Cells by Surrogate T Cell Interactions Leads to Enhanced Costimulation, Secretion of TH1-Associated Cytokines, and CTL Inductive Capacity Advances in Experimental Medicine and Biology. 417: 335-343. PMID 9286383 DOI: 10.1007/978-1-4757-9966-8_55 |
0.573 |
|
| 1997 |
Shurin MR, Pandharipande PP, Zorina TD, Haluszczak C, Subbotin VM, Hunter O, Brumfield A, Storkus WJ, Maraskovsky E, Lotze MT. FLT3 ligand induces the generation of functionally active dendritic cells in mice. Cellular Immunology. 179: 174-84. PMID 9268501 DOI: 10.1006/Cimm.1997.1152 |
0.436 |
|
| 1997 |
Tüting T, Storkus WJ, Lotze MT. Gene-based strategies for the immunotherapy of cancer Journal of Molecular Medicine. 75: 478-491. PMID 9253711 DOI: 10.1007/S001090050133 |
0.577 |
|
| 1997 |
Mayordomo JI, Zorina T, Storkus WJ, Zitvogel L, Garcia-Prats MD, DeLeo AB, Lotze MT. Bone marrow-derived dendritic cells serve as potent adjuvants for peptide-based antitumor vaccines. Stem Cells (Dayton, Ohio). 15: 94-103. PMID 9090785 DOI: 10.1002/Stem.150094 |
0.568 |
|
| 1997 |
Maeurer MJ, Walter W, Martin D, Zitvogel L, Elder E, Storkus W, Lotze MT. Interleukin-7 (IL-7) in colorectal cancer: IL-7 is produced by tissues from colorectal cancer and promotes preferential expansion of tumour infiltrating lymphocytes. Scandinavian Journal of Immunology. 45: 182-92. PMID 9042431 DOI: 10.1046/J.1365-3083.1997.D01-384.X |
0.375 |
|
| 1997 |
Zitvogel L, Couderc B, Mayordomo JI, Robbins PD, Lotze MT, Storkus WJ. IL-12-engineered dendritic cells serve as effective tumor vaccine adjuvants in vivo. Annals of the New York Academy of Sciences. 795: 284-93. PMID 8958940 DOI: 10.1111/J.1749-6632.1996.Tb52678.X |
0.561 |
|
| 1997 |
Tahara H, Zitvogel L, Storkus WJ, Robbins PD, Lotze MT. Murine models of cancer cytokine gene therapy using interleukin-12. Annals of the New York Academy of Sciences. 795: 275-83. PMID 8958939 DOI: 10.1111/J.1749-6632.1996.Tb52677.X |
0.498 |
|
| 1997 |
Lotze MT, Storkus WJ, Falo L, Baar J, Davis I, Tueting T, Esche C, Whiteside TL, Elder EM, Kinzler DM, Paradise C, Kirkwood JM. Dendritic cells (DCs) and the immunotherapy of melanoma Melanoma Research. 7: S4. DOI: 10.1097/00008390-199706001-00012 |
0.428 |
|
| 1997 |
Nishioka Y, Shurin M, Robbins PD, Storkus WJ, Lotze MT, Tahara H. EFFECTIVE TUMOR IMMUNOTHERAPY USING BONE MARROW (BM)-DERIVED DENDRITIC CELLS (DCS) GENETICALLY ENGINEERED TO EXPRESS INTERLEUKIN 12 Journal of Immunotherapy. 20: 419. DOI: 10.1097/00002371-199709000-00090 |
0.426 |
|
| 1997 |
Tahara H, Elder EM, Cai O, Kinzler DM, Storkus WJ, Zitvogel L, Kirkwood JM, Whiteside TL, Robbins PD, Lotze MT. PHASE I CLINICAL TRIAL OF INTERLEUKIN-12 (IL-12) CYTOKINE GENE THERAPY WITH OBJECTIVE RESPONSES IN CANCER PATIENTS WITH VARIOUS HISTOLOGIES Journal of Immunotherapy. 20: 416. DOI: 10.1097/00002371-199709000-00078 |
0.314 |
|
| 1997 |
Logan T, Elder E, Storkus W, Whiteside T. Proliferation of vaccine draining lymph node lymphocytes (VDLNL) or IVS T Cells (IVS-T) in Culture with Bryostatin and Ionomycin Journal of Immunotherapy. 20: 413. DOI: 10.1097/00002371-199709000-00065 |
0.407 |
|
| 1997 |
Hall TD, Kinzler DM, Elder EM, Whiteside TL, Storkus WJ, Lotze MT. EVALUATION AND RESPONSE OF PATIENTS IMMUNIZED TO HLA-A2 POLYPEPITOPE PEPTIDE MIXTURE IN PATIENTS WITH METASTATIC MELANOMA USING AUTOLOGOUS DENDRITIC CELLS CULTURED WITH IL-4 AND GM-CSF Journal of Immunotherapy. 20: 405. DOI: 10.1097/00002371-199709000-00033 |
0.412 |
|
| 1997 |
Tüting T, Baar J, Schurin M, Mayordomo JI, Zitvogel L, Tahara H, Storkus WJ, DeLeo A, Lotze MT. Dendritic cell-based therapy for cancer European Journal of Cancer. 33: S21. DOI: 10.1016/S0959-8049(97)89384-7 |
0.363 |
|
| 1996 |
Maeurer MJ, Chan HW, Karbach J, Salter RD, Knuth A, Lotze MT, Storkus WJ. Amino acid substitutions at position 97 in HLA-A2 segregate cytolysis from cytokine release in MART-1/Melan-A peptide AAGIGILTV-specific cytotoxic T lymphocytes. European Journal of Immunology. 26: 2613-23. PMID 8921947 DOI: 10.1002/Eji.1830261112 |
0.394 |
|
| 1996 |
Maeurer MJ, Gollin SM, Martin D, Swaney W, Bryant J, Castelli C, Robbins P, Parmiani G, Storkus WJ, Lotze MT. Tumor escape from immune recognition: lethal recurrent melanoma in a patient associated with downregulation of the peptide transporter protein TAP-1 and loss of expression of the immunodominant MART-1/Melan-A antigen. The Journal of Clinical Investigation. 98: 1633-41. PMID 8833913 DOI: 10.1172/Jci118958 |
0.567 |
|
| 1996 |
Mayordomo JI, Loftus DJ, Sakamoto H, De Cesare CM, Appasamy PM, Lotze MT, Storkus WJ, Appella E, DeLeo AB. Therapy of murine tumors with p53 wild-type and mutant sequence peptide-based vaccines Journal of Experimental Medicine. 183: 1357-1365. PMID 8666894 DOI: 10.1084/Jem.183.4.1357 |
0.49 |
|
| 1996 |
Tahara H, Lotze MT, Robbins PD, Storkus WJ, Zitvogel L. IL-12 gene therapy using direct injection of tumors with genetically engineered autologous fibroblasts. Human Gene Therapy. 6: 1607-24. PMID 8664385 DOI: 10.1089/Hum.1995.6.12-1607 |
0.366 |
|
| 1996 |
Zitvogel L, Robbins PD, Storkus WJ, Clarke MR, Maeurer MJ, Campbell RL, Davis CG, Tahara H, Schreiber RD, Lotze MT. Interleukin-12 and B7.1 co-stimulation cooperate in the induction of effective antitumor immunity and therapy of established tumors. European Journal of Immunology. 26: 1335-41. PMID 8647214 DOI: 10.1002/Eji.1830260624 |
0.53 |
|
| 1996 |
Maeurer MJ, Storkus WJ, Kirkwood JM, Lotze MT. New treatment options for patients with melanoma: Review of melanoma-derived T-cell epitope-based peptide vaccines Melanoma Research. 6: 11-24. PMID 8640065 DOI: 10.1097/00008390-199602000-00003 |
0.487 |
|
| 1996 |
Zitvogel L, Mayordomo JI, Tjandrawan T, DeLeo AB, Clarke MR, Lotze MT, Storkus WJ. Therapy of murine tumors with tumor peptide-pulsed dendritic cells: dependence on T cells, B7 costimulation, and T helper cell 1-associated cytokines. The Journal of Experimental Medicine. 183: 87-97. PMID 8551248 DOI: 10.1084/Jem.183.1.87 |
0.589 |
|
| 1996 |
Celluzzi CM, Mayordomo JI, Storkus WJ, Lotze MT, Falo LD. Peptide-pulsed dendritic cells induce antigen-specific CTL-mediated protective tumor immunity. The Journal of Experimental Medicine. 183: 283-7. PMID 8551233 DOI: 10.1084/Jem.183.1.283 |
0.563 |
|
| 1996 |
Storkus WJ, Wei M, Cresswell P, Dawson JR. Class I-like CD1A-C do not protect target cells from NK-mediated cytolysis Cellular Immunology. 167: 154-156. PMID 8548840 DOI: 10.1006/Cimm.1996.0020 |
0.395 |
|
| 1995 |
Maeurer MJ, Martin DM, Storkus WJ, Lotze MT. TCR usage in CTLs recognizing melanoma/melanocyte antigens Immunology Today. 16: 603-604. PMID 8579754 DOI: 10.1016/0167-5699(95)80084-0 |
0.386 |
|
| 1995 |
Castelli C, Storkus WJ, Maeurer MJ, Martin DM, Huang EC, Pramanik BN, Nagabhushan TL, Parmiani G, Lotze MT. Mass spectrometric identification of a naturally processed melanoma peptide recognized by CD8+ cytotoxic T lymphocytes. The Journal of Experimental Medicine. 181: 363-8. PMID 7807017 DOI: 10.1084/Jem.181.1.363 |
0.416 |
|
| 1995 |
Zitvogel L, Tahara H, Cai Q, Storkus WJ, Muller G, Wolf SF, Gately M, Robbins PD, Lotze MT. Construction and characterization of retroviral vectors expressing biologically active human interleukin-12. Human Gene Therapy. 5: 1493-506. PMID 7711142 DOI: 10.1089/Hum.1994.5.12-1493 |
0.452 |
|
| 1995 |
Maeurer MJ, Martin DM, Castelli C, Elder E, Leder G, Storkus WJ, Lotze MT. Host immune response in renal cell cancer: interleukin-4 (IL-4) and IL-10 mRNA are frequently detected in freshly collected tumor-infiltrating lymphocytes. Cancer Immunology, Immunotherapy : Cii. 41: 111-21. PMID 7656270 DOI: 10.1007/Bf01527407 |
0.494 |
|
| 1995 |
Mayordomo JI, Zorina T, Storkus WJ, Zitvogel L, Celluzzi C, Falo LD, Melief CJ, Ildstad ST, Kast WM, Deleo AB, Lotze MT. Bone marrow-derived dendritic cells pulsed with synthetic tumour peptides elicit protective and therapeutic antitumour immunity Nature Medicine. 1: 1297-1302. PMID 7489412 DOI: 10.1038/Nm1295-1297 |
0.45 |
|
| 1995 |
Zavoral TW, Tjandrawan T, Mayordomo JI, Storkus WJ, Lotze MT. ENHANCED GENERATION OF HUMAN DENDRITIC CELLS FROM PERIPHERAL BLOOD MONONUCLEAR CELLS BY MONOCYTE DEPLETION WITH L-LEUCYL-L-LEUCINE METHYL ESTER Journal of Immunotherapy. 18: 136. DOI: 10.1097/00002371-199508000-00043 |
0.321 |
|
| 1995 |
Couderc B, Zitvogel L, Tahara H, Storkus W, Lotze M, Robbins P. CANCER GENE THERAPY USING IL-4, IL-12 OR IL-15 WITH THE COSTIMULATORY MOLECULES CD27, CD30, CD40 OR B7.1 Journal of Immunotherapy. 18: 131. DOI: 10.1097/00002371-199508000-00022 |
0.39 |
|
| 1995 |
Maeurer J, Martin DM, Castelli C, Elder E, Leder G, Storkus WJ, Lotze MT. Host immune response in renal cell cancer: Interleukin-4 (IL-4) and IL-10 mRNA are frequently detected in freshly collected tumor-infiltrating lymphocytes Cancer Immunology, Immunotherapy. 41: 111-121. DOI: 10.1007/s002620050207 |
0.315 |
|
| 1994 |
Zeh HJ, Leder GH, Lotze MT, Salter RD, Tector M, Stuber G, Modrow S, Storkus WJ. Flow-cytometric determination of peptide-class I complex formation. Identification of p53 peptides that bind to HLA-A2. Human Immunology. 39: 79-86. PMID 8175386 DOI: 10.1016/0198-8859(94)90105-8 |
0.378 |
|
| 1994 |
Zeh HJ, Hurd S, Storkus WJ, Lotze MT. Interleukin-12 promotes the proliferation and cytolytic maturation of immune effectors: implications for the immunotherapy of cancer. Journal of Immunotherapy With Emphasis On Tumor Immunology : Official Journal of the Society For Biological Therapy. 14: 155-61. PMID 7904180 DOI: 10.1097/00002371-199308000-00012 |
0.494 |
|
| 1994 |
Tahara H, Zitvogel L, Storkus WJ, McKinney TG, Robbins PD, Lotze MT. CANCER GENE THERAPY USING INTERLEUKIN-12 (IL-12) Journal of Immunotherapy. 16: 245. DOI: 10.1097/00002371-199410000-00053 |
0.308 |
|
| 1993 |
Lotze MT, Storkus WJ, Hurd SD, Maeurer MJ, Kirkwood JM. Immunotherapy of melanoma Melanoma Research. 3: 5-6. DOI: 10.1097/00008390-199303000-00009 |
0.326 |
|
| 1993 |
Frassanito A, Mayordomo JI, Storkus WJ, Lotze MT, DeLeo R, DeLeo AB. IDENTIFICATION OF A CLASS I MHC-ASSOCIATED PEPTIDE DERIVED FROM THE METH A SARCOMA AND RECOGNIZED BY CD8+ T CELLS Journal of Immunotherapy. 14: 369. DOI: 10.1097/00002371-199311000-00062 |
0.48 |
|
| 1993 |
Storkus WJ, Zeh HJ, Salter RD, Lotze MT. Identification of T-Cell Epitopes Journal of Immunotherapy. 14: 94-103. DOI: 10.1097/00002371-199308000-00003 |
0.426 |
|
| 1993 |
Berman RM, Zeh HJ, Storkus WJ, Lotze MT. INTERLEUKIN-10 INDUCES LYMPHOKINE-ACTIVATED KILLER (LAK) CELL ACTIVITY Journal of Immunotherapy. 13: 56. DOI: 10.1097/00002371-199301000-00011 |
0.35 |
|
| 1990 |
Miller MF, Mitchell TG, Storkus WJ, Dawson JR. Human natural killer cells do not inhibit growth of Cryptococcus neoformans in the absence of antibody Infection and Immunity. 58: 639-645. PMID 2407651 DOI: 10.1128/iai.58.3.639-645.1990 |
0.305 |
|
| Show low-probability matches. |